Glycophos

Glycophos is a prescription‑only solution for injection that contains sodium glycerophosphate pentahydrate as its active ingredient; the specific strength is not disclosed in the available data. It is classified as a phosphate supplement and is marketed in the European Union for intravenous use to support phosphate balance in clinical settings. The formulation is for hospital use where rapid correction of phosphate deficiency is needed, supplied in sterile single‑use vials.

Glycophos is indicated for conditions in which serum phosphate levels are low or at risk of becoming low, particularly in hospitalized patients.

- Treatment of hypophosphatemia associated with critical illness, surgery, or trauma. - Phosphate supplementation during total parenteral nutrition (TPN) when oral intake is insufficient. - Management of phosphate depletion in patients receiving continuous renal replacement therapy. - Correction of metabolic acidosis that requires phosphate as part of the buffer system. - Support of bone mineralization in prolonged intensive‑care stays where phosphate loss is significant.

Adverse reactions to Glycophos are generally related to the intravenous administration of phosphate and may vary in frequency and severity.

Common: - Transient hyperphosphatemia that resolves without intervention. - Mild electrolyte disturbances such as hypocalcemia secondary to phosphate infusion. - Local irritation or pain at the injection site. - Nausea or mild gastrointestinal discomfort. - Transient increase in serum magnesium levels. - Mild fever or chills during infusion.

Serious: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Acute kidney injury or worsening renal function. - Allergic reactions including rash, urticaria, or anaphylaxis. - Metabolic alkalosis from rapid phosphate shifts. - Cardiovascular instability such as hypotension or arrhythmia. - Severe metabolic acidosis if phosphate administered too rapidly.

When using Glycophos, clinicians should assess patient-specific factors and monitor laboratory values to minimize risks associated with phosphate replacement.

- Verify baseline serum phosphate, calcium, magnesium, and renal function before administration. - Adjust dose in patients with renal impairment or on dialysis. - Avoid rapid infusion rates; follow recommended administration guidelines to prevent precipitation. - Monitor serum phosphate and calcium levels frequently during and after infusion. - Use caution in patients with a history of hypersensitivity to phosphate products. - Consider the risk of hyperphosphatemia in individuals receiving concurrent phosphate-containing nutrition or medications. - Discontinue if signs of severe electrolyte imbalance or allergic reaction develop.

Phosphate infusion can interact with several medications and solutions; awareness of these interactions helps prevent adverse events.

Avoid: - Concurrent administration with calcium-containing IV solutions, which may precipitate calcium phosphate. - Simultaneous use of iron dextran or other iron complexes that can bind phosphate. - Co‑infusion with high‑dose vitamin D preparations that increase intestinal phosphate absorption. - Administration with bicarbonate solutions may cause precipitation and should be avoided.

Use with caution: - Loop diuretics, which can enhance renal phosphate loss and affect serum levels. - Antacids containing aluminum or magnesium, which may alter phosphate balance. - Renal replacement therapies, where timing of phosphate infusion relative to dialysis is important.